Flagship Founder and CEO
@NoubarAfeyan joined
@LizClaman on
@FoxBusiness’ The Claman Countdown to discuss the Phase 3 trial data for
@Merck and #
FlagshipFounded#
@moderna_tx’s mRNA-based therapy for melanoma.
The results mark the first positive Phase 3 trial for an individualized neoantigen therapy and for an mRNA-based cancer therapy — a major milestone for personalized cancer treatment.
Watch the full conversation here: